A5075821470- Prenatal Substance Exposure Effects
- Maternal Mental Health During Pregnancy and Postpartum
- Opioid Use Disorder Treatment
- Gestational Diabetes Research and Management
- Breastfeeding Practices and Influences
- Homelessness and Social Issues
- Grief, Bereavement, and Mental Health
- Birth, Development, and Health
- Neuroscience of respiration and sleep
- Substance Abuse Treatment and Outcomes
- Female Genital Mutilation/Cutting Issues
- HIV/AIDS Research and Interventions
- Food Security and Health in Diverse Populations
- Maternal and Perinatal Health Interventions
- Pain Management and Opioid Use
- Migration, Health and Trauma
- Maternal and fetal healthcare
- HIV, Drug Use, Sexual Risk
- Anesthesia and Sedative Agents
- Pharmacological Effects and Toxicity Studies
- HIV-related health complications and treatments
- Mental Health and Patient Involvement
- Genital Health and Disease
- Reproductive Health and Contraception
- Hepatitis C virus research
Boston Medical Center
2015-2025
Boston University
2007-2023
Community Link
2020
Massachusetts General Hospital
2018-2020
Danish Geodata Agency
2020
SMB (Belgium)
2020
The Peter and Elizabeth C. Tower Foundation
2018
October 6 University
2018
Harvard University
2018
Albert Einstein College of Medicine
2017
Background: The Academy of Breastfeeding Medicine (ABM) revised the 2015 version substance use disorder (SUD) clinical protocol to review evidence and provide updated literature-based recommendations related breastfeeding in setting SUD treatments. Key Information: Decisions around are an important aspect care during peripartum period, there specific benefits risks for substance-exposed mother–infant dyads. Recommendations: This provides nonprescribed opioid, stimulant, sedative-hypnotic,...
This cross-sectional study examines data across 17 birthing hospitals before and after a policy change at Boston Medical Center in how reporting decisions are made cases of prenatal substance exposure.
Buprenorphine is a highly effective treatment for opioid use disorders, but its continuation in the perioperative setting remains controversial, unlike accepted practice of methadone continuation.We conducted retrospective cohort study from 2006 to 2014 comparing post-cesarean section analgesic requirements women with disorders treated or buprenorphine. Preoperative, intraoperative, and postoperative (morphine equivalent dose [MED]), complications, length stay were compared between...
To describe the characteristics, treatment, and outcomes of pregnant women with opioid use disorder.Women attending an obstetric addiction recovery clinic in Boston from 2015 to 2016 were enrolled a prospective cohort study followed through delivery (N=113). Buprenorphine or methadone was initiated clinically. The Addiction Severity Index administered at enrollment. Prenatal data systematically abstracted medical charts.Most non-Hispanic white (80.5%) mean age 28 years. Few married (8.9%)....
The Grayken Center for Addiction at Boston Medical includes programs across the care continuum people with substance use disorders (SUDs), serving both inpatients and outpatients. These had to innovate quickly during COVID-19 outbreak maintain access care. Federal state regulatory flexibility allowed these initiate treatment experiencing homelessness maximize patient safety through physical distancing practices. Programs switched telehealth high levels of acceptability retention. Some also...
The COVID-19 pandemic has directly impacted integrated substance use and prenatal care delivery in the United States driven a rapid transformation from in-person to hybrid telemedicine model. Additionally, changes regulations for take home dosing methadone treatment opioid disorder due have pregnant postpartum women. We review literature on models discuss our experience with during at New England's largest safety net hospital national leader care. In patient-centered medical patients...
Amid the current US opioid crisis, hepatitis C virus (HCV) infection rates continue to rise in young adults, including among pregnant women, yet few studies describe linkage care and treatment or postpartum women with HCV infection. We used electronic health record data estimate for before (January 2014-September 2016) during (October 2016-March 2018) implementation of a maternal-infant program combination multidisciplinary clinic colocate mother infant care. Using Poisson regression models,...
Objective There is a lack of knowledge about the relative safety and efficacy naltrexone for treatment pregnant individuals with opioid and/or alcohol use disorder, including range outcomes, in both individual infant, over course peripartum period. Our objective was to describe these outcomes cohort on naltrexone. Methods In this prospective case series, 7 disorder (OUD) or (AUD) treated were followed from pregnancy through 12 months after delivery. Clinical protocols related during...
The objective of this study was to review changes in the prevalence opioid use disorder pregnancy, and describe prenatal care neonatal outcomes following implementation buprenorphine treatment at a large US obstetrical clinic during on-going epidemic.We conducted retrospective cohort 310 women (332 pregnancies) with disorders their neonates delivered between June 2006 December 2010 an US. Trends patient volume, characteristics by calendar year were assessed using Cochran-Armitage test linear...
Background Labetalol hydrochloride (LH) is a pharmacologic treatment for hypertensive disease (HD) in pregnancy. However, pregnant persons with substance use disorders (SUDs), LH may interfere urine drug testing. Case Summary We present 3 or postpregnant SUDs who experienced presumptive positive immunoassays fentanyl while prescribed perinatal HD. Discussion HD pregnancy can result fentanyl. Unrecognized misinterpreted, this phenomenon lead to significant consequences and postpartum...